Denali Therapeutics Inc.

NasdaqGS:DNLI Rapporto sulle azioni

Cap. di mercato: US$3.9b

Denali Therapeutics Crescita futura

Future criteri di controllo 2/6

Denali Therapeutics prevede che gli utili e i ricavi cresceranno rispettivamente di 23.4% e 59.3% all'anno. Si prevede che l'EPS crescerà di 26.5% all'anno. Si prevede che il ritorno sul capitale proprio sarà di -34.4% in 3 anni.

Informazioni chiave

23.4%

Tasso di crescita degli utili

26.5%

Tasso di crescita dell'EPS

Biotechs crescita degli utili27.3%
Tasso di crescita dei ricavi59.3%
Rendimento futuro del capitale proprio-34.4%
Copertura analitica

Good

Ultimo aggiornamento01 Nov 2024

Aggiornamenti recenti sulla crescita futura

Recent updates

Denali Therapeutics: A Promising Biotech With Revolutionary BBB-Crossing Technology

Aug 20

Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth

Jul 26
Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth

Revenues Not Telling The Story For Denali Therapeutics Inc. (NASDAQ:DNLI) After Shares Rise 25%

May 23
Revenues Not Telling The Story For Denali Therapeutics Inc. (NASDAQ:DNLI) After Shares Rise 25%

Denali Therapeutics: MPS Treatment Program Continues With End Of 2024 Data

May 13

An Intrinsic Calculation For Denali Therapeutics Inc. (NASDAQ:DNLI) Suggests It's 44% Undervalued

Apr 17
An Intrinsic Calculation For Denali Therapeutics Inc. (NASDAQ:DNLI) Suggests It's 44% Undervalued

Denali Therapeutics Inc.'s (NASDAQ:DNLI) Price Is Right But Growth Is Lacking After Shares Rocket 25%

Mar 21
Denali Therapeutics Inc.'s (NASDAQ:DNLI) Price Is Right But Growth Is Lacking After Shares Rocket 25%

Denali: Leveraging Transport Vehicle Technology For Neurological Gains

Mar 07

Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth

Feb 21
Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth

Improved Revenues Required Before Denali Therapeutics Inc. (NASDAQ:DNLI) Shares Find Their Feet

Jan 26
Improved Revenues Required Before Denali Therapeutics Inc. (NASDAQ:DNLI) Shares Find Their Feet

We're Not Very Worried About Denali Therapeutics' (NASDAQ:DNLI) Cash Burn Rate

Nov 20
We're Not Very Worried About Denali Therapeutics' (NASDAQ:DNLI) Cash Burn Rate

Investor Optimism Abounds Denali Therapeutics Inc. (NASDAQ:DNLI) But Growth Is Lacking

Oct 09
Investor Optimism Abounds Denali Therapeutics Inc. (NASDAQ:DNLI) But Growth Is Lacking

Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth

Aug 22
Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth

Denali Therapeutics Inc.'s (NASDAQ:DNLI) Intrinsic Value Is Potentially 69% Above Its Share Price

May 02
Denali Therapeutics Inc.'s (NASDAQ:DNLI) Intrinsic Value Is Potentially 69% Above Its Share Price

Analysts Are More Bearish On Denali Therapeutics Inc. (NASDAQ:DNLI) Than They Used To Be

Mar 04
Analysts Are More Bearish On Denali Therapeutics Inc. (NASDAQ:DNLI) Than They Used To Be

Here's Why We're Not Too Worried About Denali Therapeutics' (NASDAQ:DNLI) Cash Burn Situation

Feb 06
Here's Why We're Not Too Worried About Denali Therapeutics' (NASDAQ:DNLI) Cash Burn Situation

These Analysts Think Denali Therapeutics Inc.'s (NASDAQ:DNLI) Sales Are Under Threat

Nov 09
These Analysts Think Denali Therapeutics Inc.'s (NASDAQ:DNLI) Sales Are Under Threat

Denali Therapeutics proposes $250M stock offering; shares down 6% post market

Oct 18

Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth

Oct 12
Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth

Biogen, Denali begin dosing in late-stage trial of Parkinson's candidate BIIB122

Oct 10

We're Not Very Worried About Denali Therapeutics' (NASDAQ:DNLI) Cash Burn Rate

Jun 08
We're Not Very Worried About Denali Therapeutics' (NASDAQ:DNLI) Cash Burn Rate

Previsioni di crescita degli utili e dei ricavi

NasdaqGS:DNLI - Stime future degli analisti e dati finanziari passati (USD Millions )
DataRicaviGuadagniFlusso di cassa liberoLiquidità dell'operazioneAvg. Numero di analisti
12/31/2026234-377-294-25211
12/31/202565-443-437-26714
12/31/202423-412-525-33515
6/30/20241-420-402-391N/A
3/31/2024295-137-425-413N/A
12/31/2023331-145-371-358N/A
9/30/2023341-124-348-332N/A
6/30/2023343-128-321-302N/A
3/31/2023101-371-248-231N/A
12/31/2022108-326-263-245N/A
9/30/2022111-303-254-238N/A
6/30/2022112-284-234-222N/A
3/31/202283-286-243-233N/A
12/31/202149-291-220-211N/A
9/30/202135330361368N/A
6/30/202135756404410N/A
3/31/202134058415420N/A
12/31/202033671413416N/A
9/30/202024-228-150-145N/A
6/30/202028-216-183-176N/A
3/31/202026-215-193-176N/A
12/31/201927-198-169-152N/A
9/30/2019148-66-27-11N/A
6/30/2019135-55-30-15N/A
3/31/2019133-52-19-14N/A
12/31/2018129-364750N/A
9/30/20183-137-64-61N/A
6/30/20182-123-51-49N/A
3/31/20181-91N/A-24N/A
12/31/2017N/A-88N/A-77N/A
9/30/2017N/A-85N/A-77N/A
6/30/2017N/A-93N/A-76N/A
3/31/2017N/A-90N/A-75N/A
12/31/2016N/A-87N/A-72N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che DNLI rimarrà non redditizia nei prossimi 3 anni.

Guadagni vs Mercato: Si prevede che DNLI rimarrà non redditizia nei prossimi 3 anni.

Guadagni ad alta crescita: Si prevede che DNLI rimarrà non redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di DNLI ( 59.3% all'anno) crescerà più rapidamente del mercato US ( 8.8% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di DNLI ( 59.3% all'anno) crescerà più rapidamente di 20% all'anno.


Previsioni di crescita dell'utile per azione


Rendimento futuro del capitale proprio

ROE futuro: Si prevede che DNLI non sarà più redditizia tra 3 anni.


Scoprire le aziende in crescita